Trimethoprim-sulfamethoxazole oral desensitization in hemophiliacs infected with human immunodeficiency virus with a history of hypersensitivity reactions.

Important note: Information in this article was accurate in 1994. The state of the art may have changed since the publication date.

Trimethoprim-sulfamethoxazole oral desensitization in hemophiliacs infected with human immunodeficiency virus with a history of hypersensitivity reactions.

Am J Dis Child. 1991 Dec;145(12):1428-9. Unique Identifier : AIDSLINE MED/94121029
Kletzel M; Beck S; Elser J; Shock N; Burks W; Department of Pediatrics, University of Arkansas for Medical; Science, Little Rock.

Abstract: Hemophiliacs infected with human immunodeficiency virus with a history of hypersensitivity reaction to a combination product of trimethoprim and sulfamethoxazole were desensitized orally. Six of the seven patients included in the study successfully completed the desensitization protocol and received trimethoprim-sulfamethoxazole for 5 to 7 months after desensitization (mean length of treatment, 5.7 months) for prophylaxis of Pneumocystis carinii pneumonia. The small number of patients and the short follow-up allow us to suggest that oral desensitization may be an effective and inexpensive means to treat hemophiliacs infected with human immunodeficiency virus with trimethoprim-sulfamethoxazole as prophylaxis against Pneumocystis carinii pneumonia.

Keywords: Administration, Oral Adolescence Adult AIDS-Related Opportunistic Infections/*DRUG THERAPY/ETIOLOGY/ PREVENTION & CONTROL Child CD4-CD8 Ratio *CD4-Positive T-Lymphocytes Desensitization, Immunologic/*METHODS Drug Hypersensitivity/COMPLICATIONS/*DRUG THERAPY Female Follow-Up Studies Hemophilia/*COMPLICATIONS Human HIV Infections/BLOOD/*COMPLICATIONS Leukocyte Count Male Pneumonia, Pneumocystis carinii/*DRUG THERAPY/ETIOLOGY/PREVENTION & CONTROL Support, U.S. Gov't, P.H.S. Trimethoprim-Sulfamethoxazole Combination/ADVERSE EFFECTS/ *THERAPEUTIC USE CLINICAL TRIAL JOURNAL ARTICLE
940430
M9440900

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1994. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1994. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .